Accounts Receivable, after Allowance for Credit Loss, Current of Zentalis Pharmaceuticals, Inc. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Zentalis Pharmaceuticals, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • Zentalis Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2025 was $0.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Zentalis Pharmaceuticals, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $0 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $0 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $0 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $5,000,000 +$5,000,000 31 Dec 2024 10-Q 10 Nov 2025 2025 Q3
Q4 2023 $0 31 Dec 2023 10-K 26 Mar 2025 2024 FY
Q4 2021 $4,000 -$413,000 -99% 31 Dec 2021 10-K 24 Feb 2022 2021 FY
Q3 2021 $108,000 -$14,000 -11% 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $5,000 -$68,000 -93% 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $248,000 +$109,000 +78% 31 Mar 2021 10-Q 17 May 2021 2021 Q1
Q4 2020 $417,000 +$277,000 +198% 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $122,000 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $73,000 30 Jun 2020 10-Q 13 Aug 2020 2020 Q2
Q1 2020 $139,000 31 Mar 2020 10-Q 15 May 2020 2020 Q1
Q4 2019 $140,000 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.